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esponsibility of Xi’Abstract A metabolic proﬁle of plasma samples from patients undergoing heart surgery with the use
of cardiopulmonary bypass (CPB) and concurrent administration of tranexamic acid was determined.
Direct immersion solid phase microextraction (DI-SPME), a new sampling and sample preparation tool
for metabolomics, was used in this study for the ﬁrst time to investigate clinical samples. The results
showed alteration of diverse compounds involved in different biochemical pathways. The most signiﬁcant
contribution in changes induced by surgery and applied pharmacotherapy was noticed in metabolic proﬁle
of lysophospholipids, triacylglycerols, mediators of platelet aggregation, and linoleic acid metabolites.
Two cases of individual response to treatment were also reported.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Over recent years ‘-omics’ analyses have been successfully applied
in drug discovery and development [1], clinical diagnostics, and
toxicology [2]. Metabolomics refers to the analysis of lowsity. Production and hosting by Else
2
a (B. Bojko),
an Jiaotong University.molecular weight compounds in biological system, including body
ﬂuids, tissues, or cells. The diversity of such compounds in
addition to proteomics or transcriptomics allows for better under-
standing of the mechanisms and dynamics responsible for both
physiological and pathological reactions. The main objective of
metabolic ﬁngerprinting is to screen metabolite changes induced
by external stimuli and ﬁnd a model, or congeries of analytes,
which characterize this response [3]. The large variation in
chemical and physical properties of compounds as well as the
wide range of their concentration (pM–mM) [4] often requires use
of different analytical approaches in order to increase metabolite
coverage. While highly sensitive instruments provide several
opportunities for metabolic studies, they demand appropriate
sample preparation. Although metabolomics has rapidly spreadvier B.V. All rights reserved.
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sample preparation remains one of the most problematic step in the
entire process of metabolome analysis. According to a recent
review on sample preparation approaches in metabolomics,
sample-preparation protocols using conventional techniques such
as liquid–liquid extraction (LLE) or solid-phase extraction (SPE)
remove proteins and other biological molecules from biological
samples and decrease ionization suppression [3,5]. However,
in the case of LLE, analysis of polar and non-polar analytes is
performed from two different fractions, which increases the
number of samples and overall time of analysis. SPE is used for
targeted rather than global metabolomics due to its selectivity [5].
To ensure the best coverage of the compounds, protein precipita-
tion (PPT) is a preferable method [5]; however, inefﬁcient sample
cleanup can lead to signiﬁcant ionization suppression [6]. Targeted
analysis on the inﬂuence of different sample preparation methods
on matrix effect showed that suppression affects polar compounds
the most, to the extent in which the signal becomes suppressed
even below baseline when PPT is used. Moreover, in the case of
the latter method, cumulative matrix effect can occur and
invalidate the ﬁrst set of injected samples, including quality
control (QC) [6]. To avoid ion suppression, cleaner sample
preparation methods should be used.
Solid phase microextraction (SPME) is a sample preparation
method based on diffusion of free analyte to extraction phase [7].
For global metabolomics, SPME is mostly used for volatile
compounds, while its application for plasma, urine, or blood
analysis focuses on pharmacokinetics [8] and ligand–protein
studies [9–11]. The use of SPME for targeted analysis mainly
arises from the fact that there are a limited number of commer-
cially available coatings suitable for extraction from complex
biological samples. Recently, an extensive study on evaluation of
SPME coatings for global metabolomics was performed indicating
three out of 42 sorbents tested the most suitable for simultaneous
extraction of hydrophobic and hydrophylic compounds [12].
The sample preparation step involves only direct extraction from
plasma (or other bioﬂuid) followed by desorption in an appropriate
solvent. Simplicity of the procedure enables avoiding the loss of
analyte as well as their chemical modiﬁcation during sample
preparation. Solvent-free extraction ensures the lack of dilution,
which is an important feature considering the low concentrations
of most of the endogenous compounds. Since the volume of
extraction phase is very small and the nature of SPME extraction is
non-exhaustive, the amount of extracted analyte is very small. This
feature provides an advantage over exhaustive standard extraction
techniques since the amount of co-extracted compounds causing
ion suppression is minimal [12]. Biocompatibility of SPME probes
used for the aforementioned studies provides restricted access to
large biomolecules such as proteins, and prevents fouling of the
coating. Due to their biocompatibility and small dimensions,
SPME ﬁbers can be used for in vivo experiments. In such cases
SPME combines several steps of the entire procedure, including
sampling, metabolism quenching, and extraction [13]. Due to the
restrictions of regulatory institutions regarding human studies,
SPME cannot be used for in vivo extraction from blood. However,
metabolomics studies with the use of collected samples can still be
performed. Since the SPME extraction phase equilibrates with a free
fraction of analyte, the results obtained provide information about
metabolites, which are biologically active and able to interact with
receptors.
Excessive bleeding after cardiopulmonary bypass (CPB) is one
of the most common complications of cardiac surgery. Tranexamicacid (TXA) is a forefront antiﬁbrinolytic agent used in cardiac
surgery [14–16] which competitively inhibits the activation of
plasminogen to plasmin and directly inhibits plasmin activity at
much higher doses. It was also reported that lysine analogs such as
tranexamic acid prevent prothrombotic and proatherogenic lipo-
protein(a) (Lp(a)) assembly in vitro [17]. On the basis of in vivo
studies with transgenic mice, it was hypothesized that lysine
analogs increase plasma Lp(a) levels by increasing the dissociation
of cell-bound apo(a) in combination with reducing Lp(a) catabo-
lism [18]. Recently, several cases of post-operative seizures were
reported in patients administered with high dose of TXA who
underwent heart surgeries with the use of CPB [19,20]. Moreover,
the administration of TXA is associated with clinically signi-
ﬁcant cerebral vasospasm with acute cerebral hemorrhage [21].
The metabolomic analysis presented herein was performed parallel
to pharmacokinetics study on a group of patients undergoing heart
surgery with the use of CPB and administered with this anti-
ﬁbrynolytic agent [15]. As mentioned previously, high concentra-
tion of TXA may result in various side effects, thus the global
view of biochemical changes induced by TXA and surgical
procedure could provide new insight into pathways responsible
for these reactions.
The objective of this study was to employ SPME for human
metabolome analysis in patients undergoing heart surgery with the
use of cardiopulmonary bypass. In addition to standard anesthesia,
patients received TXA to prevent excessive bleeding. Direct
extraction from plasma with the use of SPME mix-mode probes
was followed by liquid chromatography separation and analysis on
benchtop orbitrap mass spectrometer.2. Materials and methods
2.1. Chemicals and materials
Tranexamic acid (trans-4-(Aminomethyl)-cyclohexanecarboxylic
acid) was purchased from Sigma-Aldrich (Oakville, Canada).
Acetonitrile (LC/MS grade) and water (LC/MS grade) were
purchased from Fisher Scientiﬁc (Ottawa, Canada). Prototypes of
biocompatible SPME mix-mode probes (C18 with benzenesulfonic
acid, 45 mm thickness, 1.5 cm length of coating) were provided by
Supelco (Bellefonte, PA, USA).
2.2. Patients and blood sampling procedure
Ten patients undergoing cardiac surgery with the use of extra-
corporeal circulation (cardiopulmonary bypass, CPB) participated
in the study. All patients received the standard perioperative care
previously developed in Toronto General Hospital. After induction
of anesthesia, TXA was administered intravenously by a 30 mg/kg
bolus infused over 15 min using an infusion pump followed by an
infusion of 16 mg/kg/h until closure of the sternotomy with a
2 mg/kg load within the pump prime. Blood samples were ﬁrst
taken at baseline and then taken 5 min after the bolus. Once the
infusion had begun, samples were taken immediately before and
after commencing bypass, followed by 30-min intervals whilst on
cardiopulmonary bypass, and 5 min after chest closure. Upon
discontinuation of the infusion, samples were taken at 1, 2, 3, 4, 6,
8, 10, and 24 h. Each blood sample was collected into standard
citrate collecting tubes which were inverted a minimum of ﬁve
times to ensure proper mixing with anti-coagulant. Samples were
randomly assigned a number and thus blindly transported to the
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then centrifuged at 2000g for 15 min at 4 1C with the subsequent
supernatant frozen and stored at −70 1C until analysis. For metabo-
lomics purpose, two sets of samples were chosen for analysis—before
tranexamic acid administration (baseline) and 60 min after being placed
onto cardiopulmonary bypass and drug administration. Thus, patients
acted as their own controls. These two sets of samples were assigned as
non-dosed (ND) and dosed (D) groups.
Exclusion criteria for the studies were documented as allergy to
tranexamic acid, renal impairment, creatinine level 4130 μM,
deep hypothermic circulatory arrest, pre-existing coagulopathy,
and pregnancy.
2.3. Sample preparation
Biocompatible mix-mode probes (octadecyl and benzenesulfonic
acid groups) were used for the studies. Prior to use, all ﬁbers
underwent preconditioning by overnight exposure to methanol:
water (1:1, v/v). The SPME experiment was performed using
300 μL plasma aliquots and 60 min extraction time with 1000 rpm
vortex agitation (model DVX-2500, VWR International, Missis-
sauga, ON, Canada). Immediately following extraction, ﬁbers were
rinsed in puriﬁed water for 30 s to remove any remains of
biological material from the coating surface. As a desorption
solvent, 300 μL acetonitrile:water, (1:1, v/v) was used. Desorption
time was 60 min with vortex agitation 1000 rpm. Extracts were
further injected to LC–MS system for analysis.
2.4. LC–MS analysis
Analysis of the samples obtained from SPME experiment was
performed on the LC–MS system consisting of the Accela
autosampler with cooled system tray, Accela LC Pumps, and
Exactive Orbitrap mass spectrometer (Thermo, San Jose, CA,
USA). A chromatographic reverse phase separation method was
performed using pentaﬂuorophenyl column (Supelco Discovery
HS F5, 2.1 mm 100 mm, 3 mm). The injected extract volume
was 10 μL. Mobile phase A consisted of water/formic acid (99.9/
0.1, v/v) and mobile phase B consisted of acetonitrile/formic acid
(99.9/0.1, v/v). The ﬂow rate of mobile phase was 300 mL/min.
The following gradient elution was used: 100% A from 0 to
3.0 min, followed by a linear gradient to 10% A from 3.0 to
25.0 min, and an isocratic hold at 10% A until 34.0 min. The
total run time was 40 min/sample, including a 6 min column
re-equilibration time. MS experiments were performed with an
electrospray-ionization orbitrap mass spectrometer operating in
positive mode. Detailed information about LC method as well as
MS conditions is described elsewhere [12].
QC samples were prepared by pooling 20 μL of aliquots of all
samples used in studies. The importance of column equilibration
and system conditioning in order to obtain repeatable results has
been previously stated [22]; therefore, several injections of QC
samples were performed for system equilibration. Extracts obtained
after desorption of metabolites were injected in duplicates into
LC–MS system in random order. Every eight injections of examined
patients' samples were followed by blank and QC injections.
2.5. Multivariate statistics
Multivariate analysis was performed using SIEVE software v1.2.0
(Thermo, San Jose, CA, US). For framing 0.005 mass window,1.0 min retention time window, maximum number of frames of
20,000, and a minimum signal intensity of 10,000 were used.
Initial 1.0 min (column void volume) and ﬁnal 5.0 min of the
chromatographic run time (re-equilibration of the column) were
excluded from data processing. Further procedures involved
manual peak picking step where each signal reported by the
software was veriﬁed according to peak shape and abundance in
order to remove all variables present in blank samples or those
with an unacceptable peak shape. Multivariate analysis containing
Principal Component Analysis (PCA) with Pareto scaling and
Partial Least Squares Discriminant Analysis (PLS-DA) was
performed using SIMCA P+v12.0 software (Umetrics, Sweden).
Discriminant compounds with absolute VIP value higher than 2
were selected for identiﬁcation. The identiﬁcation was performed
through comparison of accurate mass of the feature of interest with
data collected in Human Metabolome Database (HMDB) [23]. For
searching 0.005 Da window mass was used. Subsequently, polar-
ity (deﬁned by log P) of all hits found in HMDB was veriﬁed
against experimental retention time to reduce the number of
potential compounds. In the next step, the experimental extracted
ion chromatograms (XIC) were compared with simulated spectra
of the respective hits found in the HMDB. Xcalibur software
Version 2.1 (Thermo, San Jose, CA, US) was used for this analysis.3. Results and discussion
3.1. Metabolome proﬁle in dosed (D) vs. non-dosed (ND)
patients
Prior to PCA, chromatographic alignment was employed. In all
cases alignment score was 40.9 and for most cases the alignment
score was 40.98. The software also enabled the ﬁnding of
metabolites with signiﬁcantly different intensities in studied
groups by determination of p-value (t-test) for the expression ratio
of each variable. The statistical level of conﬁdence was 95%. The
number of detected molecular features was 1009.
Footprinting analysis requires very careful control of data
quality in order to avoid analysis of changes caused by instru-
mental errors and to obtain repeatable results. Blank and QC
samples arranged throughout the entire sequence show very good
clustering, thereby indicating good system stability (Fig. 1).
The details of intensity, mass accuracy and retention time stability
in the QC samples can be found in the Supplementary information.
Based on the obtained data, three principal components were
found using cross-validation. The created PCA model (Fig. 1)
presents good separation between samples obtained from the
patients before (non-dosed; ND) and during surgery and drug
administration (dosed; D) as well as the existence of four samples
outside the Hotelling T2 ellipse symbolizing 95% conﬁdence level.
The observed outliers represent samples obtained from two
patients (7D and 9D) measured in duplicates. The ﬁrst three
principal components explain ca. 60% of the model variation (PC1
34%, PC2 14%, and PC3 10%).
In order to validate the data and ﬁnd speciﬁc features
discriminating observed changes induced by tranexamic acid
administration in patients who underwent surgery with the use
of cardiopulmonary bypass, PLS-DA analysis was applied (Fig. 2).
The supervised analysis conﬁrmed existence of outliers, which
were excluded prior to the identiﬁcation of molecular features
(MFs) contributing the most to organism's response to the medical
Fig. 1 Principal component analysis for PC1, PC2 and PC3. Good
clustering of blank and QC samples and the existence of outliers can
be observed.
Fig. 2 PLS-DA score plot showing the separation of two cohorts
(group of patients before and during surgery and drug administration).
Metabolic proﬁling by SPME–LC–MS 9procedures used. However, strong outliers 9D and 7D were further
investigated to ﬁnd individual differences in response to treatment.
Loading plot (Fig. 3) obtained on the basis of PLS-DA plot
shows distribution of variables' discriminating response to tra-
nexamic acid treatment and use of CPB. It is evident that several
MFs indicate strong contribution in samples' separation. Based on
variable inﬂuence on projection (VIP) analysis, MFs with the
absolute VIP value higher than 2 underwent further identiﬁcation.
According to theory, features with VIP score ≥1 are considered to
be statistically signiﬁcant discriminants for the model under study;
however, in the current investigations the threshold was increased
to avoid model overﬁtting due to the small cohort of study
participants. Total number of MF with VIP 41 was 115, andwith VIP42 was 38. For the metabolites contributing the most in
differentiation between dosed (D) and non-dosed (ND) group, R2
values were close to 1 and Q2 values were above 0.8. This
indicates the good abilities of these compounds to explain and
predict variances in the model. As expected, the m/z for the most
contributing compound was found to be tranexamic acid. Addi-
tional experiments with the drug standard conﬁrmed retention time
and mass accuracy of the tentative variable as TXA.
Among the identiﬁed compounds related to the response
to tranexamic acid treatment during cardiac surgery in the group
of patients studied (Table 1 and appendix to Table 1 in
Supplementary information), several classes belong to lipids, with
one of the largest being glycerophospholipids. Lysophosphatidyl-
cholines, a subclass of glycerophospholipids, are known to be
products of oxidative modiﬁcation of low-density lipoproteins
(LDL) due to hydrolysis of phosphatidylcholine in LDL by group
X secretory phospholipase A2 (sPLA2-X) [24]. It was reported
that cardiac surgery induces the reduction in circulating LDL
[25,26], the increment of Lp(a) level [26,27], and decreased
phospholipid concentration in LDL by approximately 38% [25].
At the same time, it was noted that tranexamic acid also inﬂuences
lipoprotein metabolism by inhibition of Lp(a) binding with LDL
[28], platelets [29], and increasing the dissociation of cell bound
apo(a) in combination with reducing Lp(a) catabolism [18].
In the studies, statistically signiﬁcant elevated levels of sphingo-
sine 1-phosphate (S1P) and lysophosphatidic acid (LPL) were
observed in the group when patients were dosed with TXA and
underwent surgery. Sphingosine 1-phosphate and lysophosphatidic
acid are bioactive mediators in platelets aggregation by elevation of
[Ca2+]i concentration and their shape change [30–32]. Additionally,
lysophosphatidic acid induces thrombogenic activity in human
erythrocytes [33]. It was also reported that S1P stimulates secretion
of plasminogen activator-inhibitor type-1 (PAI-1) from adipocytes,
which suggests a negative impact on ﬁbrinolysis [34]. Sphingosine
1-phosphate is released at sites of tissue injury [35] and is also
involved in the regulation of eicosanoids, important inﬂammatory
mediators production [36] that may explain the increase of S1P level
in patients' samples withdrawn during surgery. Two of the main
compounds found to contribute to differentiation between dosed and
non-dosed groups of patients were mannitol and dopamine sulfate
(DOPA). The presence of these compounds is not related to
tranexamic acid treatment or response of the organism to cardio-
pulmonary bypass. Mannitol and dopamine, the most commonly
used drugs to reduce the incidence of renal dysfunction [37], were
administered to the patients during the surgery. Cardiac surgery with
the use of CPB always causes some degree of renal injury and in 2–
5% of patients it can have the most severe form—acute renal failure
with mortality of 10–20% [38]. The use of CPB also causes a
systemic inﬂammatory response due to exposure of blood to artiﬁcial
surfaces, ischemia-reperfusion of organs, and release of endotoxin
and activation of production of various reactive oxygen species
(ROS) [39]. Additionally, mannitol has been found to be a non-
speciﬁc scavenger of hydroxyl radicals [40]. Another discriminant
compound was identiﬁed as tryptophan. There was no relationship
between the increase of tryptophan concentration and tranexamic
acid treatment reported in the literature. However, elevated level of
this amino acid can be explained by DOPA administration.
Dopamine acts as inhibitor of tryptophan hydroxylase, an enzyme
converting tryptophan to 5-hydroxytryptophan (5-HTP), which is an
initial metabolite in synthesis of neurotransmitter serotonine [41].
High concentration of tranexamic acid may lead to neurological
effects such as seizures due to the competitive inhibition of
Fig. 3 Loading plots for components 1 and 2 (A) and 2 and 3 (B) showing variables differentiating dosed and non-dosed group of patients.
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to the cerebral vasospasm [21]. Despite the fact that the patients
from investigated group showed higher concentration of tranexa-
mic acid than predicted theoretically (4800 μM) [15],
no changes in metabolome proﬁle indicating the existence of
neurological disorders were found, which corroborates clinical
observations of the patients. The same pharmacokinetic studies
initially suggested the possibility of decreased elimination of
TXA due to temporary kidney failure, but there was no
conﬁrmation in metabolomics analysis. Indeed, the follow up
studies performed on the new set of samples with extended
sampling time on discontinuation of CPB and TXA bolus
reviewed the possible renal dysfunction and showed absolute
elimination of TXA several hours after discontinuation of CPB
and the drug administration.3.2. Outliers: individual changes in metabolome proﬁle in
patients during surgery
As mentioned previously, two outliers (patients 9 and 7) that
belonged to group D were observed in PCA and PLS-DA plots
(Figs. 1 and 2, respectively). Analysis of metabolites contri-
buting to the differences between patient 9 and the remainder
of patients in group D showed the deviation from the averagein the concentration of metabolites previously identiﬁed as
discriminant compounds: mannitol, lypophospolipids, tryptophan,
and eicosapentanoic acid. Herein, positive changes in phospholipid
concentration were additionally associated with the increased
plasma level of linoleic acid metabolites (9-HODE; 12,13-
EpOME; 9,10-Epoxyoctadecenoic acid; 9-HOTE; 9(10)-EpODE;
15(16)-EpODE; 13-HOTE; A-12(13)-EpODE; 9-OxoODE;
13-OxoODE; 17-Hydroxylinolenic acid; 9-HOTE; 9(10)-EpODE;
15(16)-EpODE; 13-HOTE; A-12(13)-EpODE; 9-OxoODE;
9,10-DHOME; 9,10-DiHOME; 13-OxoODE; 9,10-DiHODE; 15,16-
DiHODE; 12,13-DiHODE; 9(S)–HPODE; 9,10-DiHODE; 15,16-
DiHODE; 12,13-DiHODE; 9(S)-HPODE). Linoleic acid meta-
bolites are also peroxisome proliferator-activated receptor-γ
(PPAR-γ) ligands. Some, such as hydroxylinoleic acid (9-HODE),
inhibit ﬁbrinolysis by increasing expression of plasminogen
activator-inhibitor type-1 (PAI-1) [42].
The 9,10-dihydroxy-12Z-octadecenoic acid (9,10-DHOME;
9,10-DiHOME), metabolite of epoxyoctadecenoic acids (EpOME),
exhibited the highest contribution among the abovementioned
linoleic acid derivatives in differentiation of outlier 9D. Distribu-
tion of the DHOME in the studied cohort is shown in Fig. 4A.
There has been no reported evidence that DHOMEs have
antiﬁbrinolitic properties; however, DHOMEs are known to be
involved in numerous biochemical pathways [43–47]. For exam-
ple, DHOMEs were found to suppress neutrophil respiratory burst
Table 1 Tentative compounds contributing in differentiation between non-dosed (ND) and dosed (D) groups of patients. List of hits
found in the Human Metabolome Database for chosen compounds differentiating studied group of patients. Mass window: 5 ppm.
Class Subclass Name
Cycloalkanes N/A Tranexamic acid
Amino acids and
derivatives
Alpha amino acids and derivatives L-Tryptophan; N-Decanoylglycine; DOPA sulfate; D-Proline; L-Proline;
N-Nonanoylglycine; Tryptophanamide
Alcohols and polyols Cholines Undecanoylcholine
Tetrapyrroles and
derivatives
Bilirubins D-Urobilinogen
Indolequinones N/A Indole-5,6-quinone
Benzaldehydes N/A Gentisate aldehyde
Glycerolipids Triacylglycerols nFull list of triacylglycerols can be found in appendix to Table 1 in the
Supplementary information
Monoacylglycerols D-Glucopyranosiduronic acid
MG(24:6(6Z,9Z,12Z,15Z,18Z,21Z)/0:0/0:0)
MG(0:0/24:6(6Z,9Z,12Z,15Z,18Z,21Z)/0:0)
Glycosylglycerols 1,2-Dioctadecanoyl-3-(galactosyl-B-1-6-galactosyl-B-1)-glycerol
Glycerophospholipids Glycerophosphoethanolamines nFull list of glycerophosphoethanolamines can be found in appendix to Table 1 in
the Supplementary information
Glycerophosphocholines nFull list of glycerophosphocholines can be found in appendix to Table 1 in the
Supplementary information
Glycerophosphates LPA(18:0/0:0); LPA(0:0/18:0); LPA(0:0/18:1(9Z)); LPA(18:1(9Z)/0:0)
Steroids and steroid
derivatives
Cholesterols and derivatives 3 Beta,7 alpha-Dihydroxy-5-cholestenoate
Steroids and steroid derivatives/bile
acids, alcohols and derivatives
Chenodeoxyglycocholic acid; Glycoursodeoxycholic acid; 3b,4b,7a,12a-
Tetrahydroxy-5b-cholanoic acid; 2b,3a,7a,12a-Tetrahydroxy-5b-cholanoic acid;
3a,6b,7b,12b-Tetrahydroxy-5b-cholanoic acid; 3a,7a,12a,19-Tetrahydroxy-5b-
cholanoic acid; 3a,4b,7a,12a-Tetrahydroxy-5b-cholanoic acid; 1b,3a,7b-
Trihydroxy-5b-cholanoic acid; 3a,6b,7a,12a-Tetrahydroxy-5b-cholanoic acid;
Lithocholic acid glycine conjugate; Glycocholic acid
Steroidal glycosides Deoxycholic acid 3-glucuronide
Gluco/mineralocorticoids,
progestogins and derivatives
3a,7b,21-Trihydroxy-5b-cholanoic acid; 3a,6b,7b,12a-Tetrahydroxy-5b-cholanoic
acid; 3a,7b,12a-Trihydroxyoxocholanyl-Glycine
Sphingolipids Neutral glycosphingolipids Ganglioside GA2 (d18:1/12:0)
Ceramides Trihexosylceramide (d18:1/12:0)
Ceramide (d18:1/25:0)
N/A Sphingosine 1-phosphate
Fatty alcohols N/A Mannitol
Fatty acid esters Acyl carnitines Docosa-4,7,10,13,16-pentaenoyl carnitine
Cervonyl carnitine
Fatty acids and
conjugates
Hydroxy fatty acids 9,10-DHOME; 12,13-DHOME
Branched fatty acids Alpha-ketoisovaleric acid
2-Methylacetoacetic acid
Straight chain fatty acids Glutarate semialdehyde
Prenol lipids Sesterterpenes 7 alpha-Hydroxy-3-oxo-4-cholestenoate
Keto-acids and
derivatives
Short-chain keto acids and
derivatives
2-Oxovaleric acid
Sugar acids and
derivatives
Sugar amino acids and derivatives N-Acetyl-7-O-acetylneuraminic acid
N-Acetyl-4-O-acetylneuraminic acid
N-Acetyl-9-O-acetylneuraminic acid
Metabolic proﬁling by SPME–LC–MS 11[43], have proinﬂammatory effect [44], positive inotropic actions
on the isolated rat heart [45], and neutrophil chemotactic activity
[46]. In cardiac surgery, due to the contact of patient blood with
artiﬁcial surfaces of the extracorporeal circuits, activation of the
immune system through the neutrophil chemotaxis may occur[47]. In turn, this can lead to postoperative organ dysfunction.
Enhanced responsiveness of circulatory neutrophils after cardiac
surgery with CPB has been reported previously [47]. Current
results may suggest that DHOME can participate in neutrophils
activation pathway in patients undergoing heart surgery with CPB
Fig. 4 Individual changes in response to surgery and drug administration. Distribution of m/z 315.25 (A) and 450.32 (B) variables among the
studied group of patients shows signiﬁcant increase of their level in plasma samples of patient 9D and patient 7D, respectively.
B. Bojko et al.12and concurrent administration of TXA; however, further studies
should be performed to verify this theory.
Two pairs of the observed outliers have different projections on
PCA and PLS-DA plots (Figs. 1 and 2, respectively). This points
to variables characterizing a difference in metabolic proﬁling of
these patients. Indeed, a comparison of metabolites contributing to
differentiation between patient 7 and the remainder of group D
indicates that the most discriminating compounds belong to bile
acids and phosphatidylcholines. As an example, distribution of
cholic acid (adduct M+ACN+H; m/z 450.3204) in the studied
cohort is presented in Fig. 4. Post-operative clinical observation
did not show functional liver changes in this patient.4. Conclusion
Results indicate that SPME coupled with LC–MS platform can be
successfully used for studies of human metabolic ﬁngerprinting.
With the use of a new extraction phase it is possible to extract
compounds with different chemical and physical properties with-
out any prior sample preparation steps directly from plasma
aliquots. Since SPME extraction phase is at the equilibrium with
a free fraction of analyte, the results obtained provide information
about metabolites, which are biologically active and are able to
interact with receptors.
The current proof-of-concept study was performed on a small
cohort with satisfactory separation between samples collected prior
to and during surgery, and administration of tranexamic acid was
achieved. The most signiﬁcant contribution to changes induced by
the medical procedure and pharmacotherapy used was observed in
metabolic proﬁle of lysophospholipids, mediators of platelet aggre-
gation, triacylglycerols, and linoleic acid metabolites. The analysis of
metabolic proﬁles of patients observed as outliers provides additional
insight into individual response to treatment employed or medical
condition of the patient, which can be used in personalized
therapy. Up-regulation of 9,10-dihydroxy-12Z-octadecenoic acid
and/or 12,13-dihydroxy-12Z-octadecenoic acid (9,10-DHOME and12,13-DHOME, respectively) found in one outlier case possibly
suggests that DHOME can play a role in neutrophil activation due to
blood contact with artiﬁcial circulatory system.
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